榮昌生物(09995.HK)RC198在澳洲獲I期臨床試驗倫理許可
榮昌生物-B(09995.HK)公布,獲得澳洲人類 究倫理委員會就產品RC198,白介素-15(IL-15)和白介素15受體(IL-15R)的Fc融合蛋白的I期臨床試驗倫理許可。公司將在澳洲開展針對局部晚期不可切除或轉移性實體瘤患者的臨床研究。
RC198是一款Fc融合蛋白產品用於治療包括尿路上皮癌、黑色素瘤、宮頸癌、結腸直腸癌、頭頸部癌、非小細胞肺癌等多種癌症。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.